Press Release

<<  Back
Printer Friendly Version   View printer-friendly version
BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate Objectives for 2016
March 21, 2016

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 21, 2016-- BioTime, Inc. (NYSE MKT:BTX) today announced that it will host a conference call on Thursday, March 31, to update investors on the Company’s recent accomplishments and objectives for the remainder of 2016. Among the highlights of the call will be an update on the clinical trials currently underway for Renevia® for lipoatrophy, and OpRegen® for dry age-related macular degeneration. In addition, management will discuss recent developments for its other clinical stage programs: AST-VAC1 cancer immunotherapy for acute myeloid leukemia, AST-OPC1 for spinal cord injury, and OncoCyte’s diagnostic programs in oncology. BioTime will also review recent corporate transactions and collaborations.

The BioTime conference call and webcast is scheduled for Thursday, March 31, 2016, and will begin at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Prepared remarks by management will be followed by a Q&A session with analysts and institutional investors following the Company.

The conference call dial-in number in the U.S./Canada is (877) 407-0784. For international participants outside the U.S./Canada, the dial-in number is (201) 689-8560. For all callers, please refer to the “BioTime, Inc. Corporate Update Conference Call.” The live webcast can be accessed on the company’s website at

A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling toll-free (from U.S./Canada) (877) 870-5176; international callers dial (858) 384-5517. Use the Conference ID 13633134. Additionally, the archived webcast will be available at

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent stem cell assets. The foundation of our core therapeutic technology platform is pluripotent stem cells that are capable of becoming any of the cell types in the human body. Pluripotent stem cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent stem cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In order to efficiently advance product candidates through the clinical trial process, we have historically created operating subsidiaries for each program and product line. This approach has fostered efficient use of resources and reduced shareholder dilution as compared to strategies commonly deployed by the biotechnology industry, as the various programs and product lines have advanced through basic research and animal studies. We and our subsidiaries now have four therapeutic product candidates in human clinical trials, each of which addresses a large market opportunity. In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and stem cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.


Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime'sSecurities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:


Source: BioTime, Inc.

BioTime, Inc.
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890